Your session is about to expire
← Back to Search
Antisense Oligonucleotide
Bepirovirsen for Chronic Hepatitis B (B-Well 2 Trial)
Phase 3
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 weeks
Awards & highlights
Summary
This trial is testing bepirovirsen, a medication that aims to lower a key protein made by the hepatitis B virus. Bepirovirsen has shown reductions in viral components in cell culture and animal models. It targets patients with specific levels of this protein in their blood. The goal is to see if bepirovirsen can better control the infection compared to current treatments.
Who is the study for?
This trial is for adults with chronic Hepatitis B who've been on stable antiviral therapy for at least 6 months, have low viral DNA levels in their blood, and normal to slightly elevated liver enzymes. They must not have other infections like HIV or Hepatitis C/D, no recent cancer except certain skin cancers, and can't be on immune-suppressing drugs or have a history of drug abuse.
What is being tested?
The study tests the effectiveness of Bepirovirsen compared to a placebo in suppressing the hepatitis B virus when taken alongside standard antiviral treatment. It's divided into stages including initial double-blind treatment, continued antiviral therapy, potential cessation of antivirals, and monitoring durability of response over approximately two years.
What are the potential side effects?
While specific side effects are not listed here, similar treatments often cause flu-like symptoms (fever, fatigue), injection site reactions (redness or pain), possible liver enzyme elevations indicating liver irritation/inflammation. Participants will be monitored closely for any adverse effects throughout the trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 72 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants achieving functional cure (FC) with baseline HBsAg ≤3000 IU/mL
Secondary study objectives
Number of participants achieving FC with baseline HBsAg ≤1000 IU/mL
Number of participants achieving sustained suppression of HBV DNA (<LLOQ) with baseline HBsAg ≤1000 IU/mL
Number of participants achieving sustained suppression of HBV DNA (<LLOQ) with baseline HBsAg ≤3000 IU/mL
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: BepirovirsenExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bepirovirsen
2023
Completed Phase 1
~160
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Chronic Hepatitis B (CHB) include nucleos(t)ide analogues and antisense oligonucleotides (ASOs). Nucleos(t)ide analogues, such as entecavir and tenofovir, inhibit the reverse transcriptase enzyme, essential for HBV DNA replication, thereby reducing viral load and liver damage.
ASOs like Bepirovirsen target HBV mRNA, preventing the production of viral proteins necessary for the virus's life cycle, which can reduce viral antigenemia and viremia. These mechanisms are crucial for CHB patients as they help in selecting effective treatments, potentially leading to better long-term outcomes and reduced liver damage.
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
Find a Location
Who is running the clinical trial?
GlaxoSmithKlineLead Sponsor
4,788 Previous Clinical Trials
8,175,936 Total Patients Enrolled
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,601 Previous Clinical Trials
6,144,143 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am willing to stop my current NA treatment as required.I cannot take immunosuppressive treatments or high doses of steroids.I am willing to stop my current NA treatment as required.I have taken interferon therapy in the last 12 months.I have or might have liver cirrhosis.I can stop my blood thinner or anti-platelet medication safely for the study.I have or might have liver cancer.I have or had vasculitis or symptoms like unexplained rashes or blood in urine.I haven't taken any gene-silencing drugs in the last year.I don't have major health issues like severe liver disease (except chronic HBV), recent heart problems, surgery, uncontrolled diabetes, or bleeding disorders.I have been on a stable hepatitis B treatment for at least 6 months.I have been treated with bepirovirsen before.I have used immunosuppressing drugs in the last 3 months, not counting short courses or topical/inhaled steroids.I have a history of immune conditions possibly linked to hepatitis B.I have or recently had Hepatitis C, HIV, or Hepatitis D.I haven't had cancer in the last 5 years, except for skin cancer that was removed by surgery.I have been on a stable hepatitis B treatment for at least 6 months.
Research Study Groups:
This trial has the following groups:- Group 1: Bepirovirsen
- Group 2: Placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Chronic Hepatitis B Patient Testimony for trial: Trial Name: NCT05630820 — Phase 3
Share this study with friends
Copy Link
Messenger